TalkMed

Take a look at these six stocks this week, including Silverlake, Genting Singapore and Hyphens Pharma.

RHB is downgrading their call on TalkMed to “hold” from “buy” previously.

TalkMed talks the talk, but can it walk the walk?

SINGAPORE (Apr 27): RHB is maintaining its “neutral” call on TalkMed Group with a lower target price of 70 cents from 72 cents previously after the group reported a weak 1Q18 set of financial results.  

SINGAPORE (Mar 28): TalkMed says its CEO, Dr Ang Peng Tiam, has resumed his medical duties at the company this week, effective March 25, following an eight-month suspension which began in Jul 2017.

SINGAPORE (Feb 21): RHB is maintaining its "neutral" call on TalkMed as CEO Dr Ang Peng Tiam is still serving his eight-month suspension, which started on Jul 25 2017 and is expected to be back on March 26 or towards the end of 1Q18.

SINGAPORE (Nov 17): TalkMed is expanding its operations in Asia by offering management services for its very own brand of Singapore Cancer Centre oncology services in China.

SINGAPORE (Nov 8): RHB has downgraded its call on TalkMed Group to “neutral” from “buy” previously while raising its target price from 69 cents to 72 cents, which implies 29 times FY18F P/E.

SINGAPORE (Oct 2): RHB is maintaining its “buy” call on TalkMed with lower 69 cents target price despite seeing huge potential in stem cells as a way of treatment, particularly for cancer.

SINGAPORE (June 28): Ang Peng Tiam, the executive director and CEO of healthcare company TalkMed Group, has been given an eight-month suspension by the Court of Three Judges on the grounds of professional misconduct.